Zobrazeno 1 - 10
of 220
pro vyhledávání: ''
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-11 (2021)
BMC Cancer
BMC Cancer
Background Immunotherapy is a crucial therapeutic approach in oncology. However, most patients with head and neck squamous cell carcinoma (HNSCC) do not derive benefit from immunotherapy. Vascular endothelial growth factor (VEGF)/VEGF Receptor 2 (VEG
Autor:
Sicheng Liang, Liang Yue, Wenqiao Qiu, Hong Li, Xin Shen, An-Guo Wu, Jing Lin, Jianming Wu, Dalian Qin, Nan Jiang
Publikováno v:
BMC Pharmacology and Toxicology, Vol 22, Iss 1, Pp 1-10 (2021)
BMC Pharmacology & Toxicology
BMC Pharmacology & Toxicology
Background Abnormally elevated xanthine oxidase (XO) activity has been verified to cause various pathological processes, such as gout, oxidative stress injury and metabolic syndrome. Thus, XO activators may exhibit above potential toxicological prope
Autor:
Przemyslaw Szafranski, Pawel Stankiewicz, Tomasz Gambin, Jason D. Heaney, Rebecca L. Maywald, Justyna A. Karolak, Edwina J. Popek
Publikováno v:
Respiratory Research, Vol 22, Iss 1, Pp 1-11 (2021)
Respiratory Research
Respiratory Research
Background Alveolar capillary dysplasia with misalignment of pulmonary veins (ACDMPV) is a rare lethal congenital lung disorder in neonates characterized by severe progressive respiratory failure and refractory pulmonary hypertension, resulting from
Publikováno v:
BMC Pharmacology and Toxicology, Vol 22, Iss 1, Pp 1-11 (2021)
BMC Pharmacology & Toxicology
BMC Pharmacology & Toxicology
BackgroundThe present study investigated the ameliorative effect of melittin, a major polypeptide in the venom of honeybee (Apis mellifera), on isoniazid-(INH) and rifampicin-(RIF) induced hepatotoxicity in male albino rats.MethodThirty rats (140-200
Autor:
Lanlan Geng, Wanfu Xu, Long Fan, Hongli Wang, Sitang Gong, Junhong Zhao, Peiyu Chen, Zhaohui Xu, Liya Xiong, Huan Chen, Jing Xie
Publikováno v:
BMC Pharmacology and Toxicology, Vol 22, Iss 1, Pp 1-9 (2021)
BMC Pharmacology & Toxicology
BMC Pharmacology & Toxicology
Background Helicobacter pylori (H. pylori) is a common pathogen in development of peptic ulcers with pyroptosis. Rabeprazole, a critical component of standard triple therapy, has been widely used as the first-line regimen for H. pylori infectious tre
Autor:
C. Nelson Hayes, Eisuke Murakami, Wataru Okamoto, Kenichiro Kodama, Takashi Nakahara, Masami Yamauchi, Kazuaki Chayama, Daiki Miki, Tomokazu Kawaoka, Masataka Tsuge, Yuji Teraoka, Hiroshi Aikata, Michio Imamura, Yasutoshi Fujii, Shinsuke Uchikawa, Atsushi Ono, Hatsue Fujino
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 40, Iss 1, Pp 1-18 (2021)
Journal of Experimental & Clinical Cancer Research : CR
Journal of Experimental & Clinical Cancer Research : CR
BackgroundThere has been a recent surge in interest in predicting biological effects associated with genomic alterations in order to implement personalized cancer treatment strategies. However, no reports have yet evaluated the utility of profiling b
Autor:
Antoine Adenis, Stephanie Clisant Delaine, Ludovic Evesque, Julien Fraisse, Brice Pastor, Marc Ychou, Caroline Mollevi, François Ghiringhelli, Thibault Mazard, Patrick Chalbos
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-7 (2021)
BMC Cancer
BMC Cancer, BioMed Central, 2021, 21 (1), pp.564. ⟨10.1186/s12885-021-08312-7⟩
BMC Cancer
BMC Cancer, BioMed Central, 2021, 21 (1), pp.564. ⟨10.1186/s12885-021-08312-7⟩
Background The chemotherapy triplet FOLFOXIRI combined to the anti-VEGF antibody bevacizumab is an option in selected patients with metastatic colorectal cancer. In this setting, RAS-mutated metastatic colorectal cancer do not benefit the same from t
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-5 (2021)
BMC Cancer
BMC Cancer
Background Chemotherapy induced nausea- vomiting (CINV) is considered as the most common, feared and most troublesome side effect of chemotherapy. NEPA (NEtupitant 300 mg + PAlonosetron 0.50 mg) is the first commercially available oral fixed-dose com
Autor:
Helena Erlandsson Harris, Karin Palmblad, Erik Sundberg, AnnaCarin Horne, Hanna Schierbeck, Ulf Andersson, Jan-Inge Henter
Publikováno v:
Molecular Medicine, Vol 27, Iss 1, Pp 1-13 (2021)
Molecular Medicine
Molecular Medicine
Background Macrophage activation syndrome (MAS) is a potentially fatal complication of systemic inflammation. HMGB1 is a nuclear protein released extracellularly during proinflammatory lytic cell death or secreted by activated macrophages, NK cells,
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-8 (2021)
BMC Cancer
BMC Cancer
Background Regorafenib has shown promising results as a second-line therapy for patients with hepatocellular carcinoma (HCC) who progressed on sorafenib. Although there have been several data regarding the efficacy of sequential therapy with sorafeni